• Introduction
• 3 min
  1. Editor's foreword

  • Prof. Ann Daly
• 47 min
  2. Introduction to drug metabolism enzymes

  • Dr. Dennis Smith
• General factors affecting drug metabolism
• 30 min
  3. General factors affecting drug metabolism: effect of physiological factors and disease 1

  • Prof. Edward T. Morgan
• 24 min
  4. General factors affecting drug metabolism: effect of physiological factors and disease 2

  • Prof. Edward T. Morgan
• 39 min
  5. Drug metabolism in liver disease

  • Dr. Nathalie Zgheib
  • Prof. Robert Branch
• 37 min
  6. Laboratory methods for the in vitro study of drug metabolism

  • Dr. Ritu Singh
• 50 min
  7. Prediction of pathways of drug metabolism

  • Dr. Maurice Dickins
• Phase I metabolizing enzymes: cytochrome P450s
• 45 min
  8. Cytochrome P450 1 family: the roles of 1A1, 1A2 and 1B1 in drug metabolism

  • Prof. F. Peter Guengerich
• 42 min
  9. CYP2 family

  • Prof. Ann Daly
• 52 min
  10. Why study the cytochrome P4503A (CYP3A) family?

  • Dr. Erin Schuetz
• 54 min
  11. Pharmacogenomics: an update

  • Prof. Magnus Ingelman-Sundberg
• Phase I metabolizing enzymes: non-cytochrome P450s
• 45 min
  12. Non-P450 oxidative metabolism: characteristics and drug substrates

  • Dr. Christine Beedham
• 53 min
  13. UDP-glucuronosyltransferases

  • Prof. Abby Collier
• Phase II metabolizing enzymes: conjugating enzymes
• 31 min
  14. Glutathione transferases

  • Prof. Ralf Morgenstern
• 31 min
  15. Arylamine N-acetyltransferases 1

  • Prof. Edith Sim
• 23 min
  16. Arylamine N-acetyltransferases 2

  • Prof. Edith Sim
• 19 min
  17. Arylamine N-acetyltransferases 3

  • Prof. Edith Sim
• 56 min
  18. Methyltransferases

  • Prof. Richard Weinshilboum
• 22 min
  19. Amino acid conjugation: mechanism and enzymology

  • Dr. Kathleen Knights
• Clinical aspects
• 33 min
  20. Clinical significance of enzyme induction and inhibition

  • Prof. Kim Brøsen
• 39 min
  21. Clinical importance of pharmacogenetic polymorphisms affecting drug metabolism

  • Prof. Julia Stingl (formerly Kirchheiner)
• Latest Updates in the Field
• 34 min
  22. Mammalian flavin-containing monooxygenases

  • Prof. Allan Rettie
• Archived Lectures *These may not cover the latest advances in the field
• 54 min
  23. Glucuronidation and the UDP - glucuronosyltransferases

  • Prof. Peter Mackenzie
  • Prof. John Miners
• 38 min
  24. General factors affecting drug metabolism: the role of nuclear receptor superfamily members in induction

  • Dr. Patrick Maurel
• 28 min
  25. Catalytic cycle of cytochrome P450s

  • Prof. Gordon Roberts
• 40 min
  26. Drug metabolism and liver disease

  • Prof. Robert Branch
• 46 min
  27. Crystal structures of drug-metabolizing P450 monooxygenases

  • Prof. Eric Johnson
• 49 min
  28. Sulfation and human cytosolic sulfotransferases

  • Prof. Charles Falany
• 50 min
  29. Laboratory methods for the in vitro study of drug metabolism

  • Dr. Charles Crespi
• 45 min
  30. Clinical importance of pharmacogenetic polymorphisms affecting drug metabolism: psychopharmacology and pain

  • Prof. Julia Stingl (formerly Kirchheiner)
• 51 min
  31. Genetic variability in Paraoxonase 1 (PON1), an HDL associated esterase: impact on risk and pharmacokinetics

  • Res. Prof. Clement Furlong
• 53 min
  32. Pharmacogenomics

  • Prof. Magnus Ingelman-Sundberg

Printable Handouts

PDF

Navigable Slide Index

1. Pharmacog. polym. & drug metab.
2. (P. I) Psychopharmacology and pain
3. Clinical pharmacogenomics
4. Genetic variability of drug response
5. Genetic variability in pharmacokin.
6. Polymorphisms in drug metabolism
7. Genetics-based dose adjustments
8. Polymorphic drug metab. enzymes
9. CYP2D6 - activity in Caucasians
10. Variability in doxepin kinetics
11. Antidep. drug treat. - problems
12. CYP2D6 in antidep. drug treat.
13. CYP2D6 polym. - antidep. drug treat.
14. CYP2D6-based dose adjustments
15. Genotype-based dose adjustments
16. Genotype-phenotype interaction
17. CYP2D6 interethnic differences
18. Influence of polymorphisms in DME
19. Types of adverse drug reactions
20. Antidepressant drug treatment
21. CYP2D6 geno. in ADR patients
22. Adverse effect of antipsychotics
23. CYP2D6 and haloperidol clearance
24. Extrapyramidal sympt. & CYP2D6
25. CYP2D6 - not just a DME
26. CYP2D6 in psychiatry - summary
27. PG polymorphisms in DME
28. Codeine
29. Morphine conc. after codeine treat.
30. CYP2D6 sedat. after codeine treat.
31. Tramadol
32. PG polymorphisms in DME
33. Metabolism of NSAIDs
34. CYP2C genetic locus
35. CYP2C9
36. CYP2C9 - pharmacok. of ibuprofen
37. CYP2C9 - prostaglandin E2
38. CYP2C9 - COX-1 inhibition
39. CYP2C9 - PK differences of NSAIDs
40. Physiologic role of CYP2C8/9
41. CYP inhibitors
42. Conclusion (pain)
43. Acknowledgments

Topics Covered

• Pharmacogenetic polymorphisms
• Biotransformation and clinical outcome
• Consequences of genotyping
• Feasibility for genotyping in antidepressant drug treatment
• Polymorphic cytochrome P450 enzyme CYP2D6
• Feasibility for genotyping in pain treatment
• CYP2C9, CYP2D6 and nonsteroidal analgetic drugs

Links

Series:

• Drug Metabolizing Enzymes

Categories:

• Biochemistry
• Metabolism & Nutrition
• Neuroscience
• Pharmaceutical Sciences

Therapeutic Areas:

• Cardiovascular & Metabolic
• Neurology

Talk Citation

Stingl (formerly Kirchheiner), J. (2007, October 1). Clinical importance of pharmacogenetic polymorphisms affecting drug metabolism: psychopharmacology and pain [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved May 13, 2025, from https://doi.org/10.69645/OUON8575.
Export Citation (RIS)

Publication History

• Published on October 1, 2007
• Archived on December 10, 2018

Financial Disclosures

• Prof. Julia Stingl (formerly Kirchheiner) has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.